Company Sponsored Symposia

The Next Headliners: TL1A and the Future of IBD Management

Bruce E. Sands, MD, MS, FACG (Chair), Maia Kayal, MD, MS, Millie D. Long, MD, MPH, FACG, Dermot P.B. McGovern, MD, PhD, FRCP, FACG
6:30 pm - 8:30 pm • Music City Center – Davidson Ballroom A

As the IBD treatment landscape continues to evolve, emerging therapies targeting novel inflammatory pathways have the potential to reshape the future of care. Through engaging presentations and Rapid-Fire Roundtable discussions, experts will examine the limitations of current treatment approaches, review the role of the TL1A pathway in IBD pathogenesis, and explore how these agents may influence future treatment decisions.

This continuing education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Merck & Co., Inc.

IBS-C Uncovered: Patient Simulation Case Challenges

Lin Chang, MD, FACG, Brian E. Lacy, MD, PhD, FACG, Baharak Moshiree, MD, MSc, FACG
5:30 pm – 7:30 pm • Omni Nashville Hotel – Legends Ballroom EFG

Irritable bowel syndrome with constipation (IBS-C) is one of the most common and vexing disorders of gut-brain interaction seen in gastroenterology practices. Using patient case simulations, expert faculty will help learners navigate the complexities of IBS-C diagnosis and management. Learners will be able to select tests and treatments while faculty provide feedback and guidance in real time, supported by the latest clinical evidence. This engaging and interactive patient simulation symposium will help to advance clinicians’ clinical decisionmaking skills in managing IBS-C patients in their practices. Attendees will come away with an in-depth understanding of IBS-C diagnosis and management, including the latest information on prescription IBS-C treatments and when to advance patients beyond over-the-counter therapies.

This activity is supported by an independent educational grant from Ardelyx.

---

Eosinophilic Esophagitis in the Spotlight: Epithelial Cytokines, From Disease Pathogenesis to Biologic Treatment

Maureen Bauer, MD; Evan S. Dellon, MD, MPH, FACG; Girish Hiremath, MD, MPH
5:30 pm – 7:30 pm • Omni Nashville Hotel – Broadway Ballroom G-K

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease with an evolving therapeutic landscape. This Science in the Spotlight™ dinner symposium begins with a dynamic whiteboard animation that engages learners and shifts clinical thinking from symptombased management toward a mechanism-driven approach to patient assessment and treatment. Faculty will explore the role of epithelial signaling and upstream alarmin cytokines in EoE pathogenesis before examining emerging biologic therapies targeting these pathways. Through interactive polling, practical clinical application, and expert discussion, attendees will gain evidence-based strategies to improve the diagnosis, evaluation, therapeutic selection, and long-term management of patients with EoE.

This activity is provided by Integritas Communications and supported by an independent medical education grant from AstraZeneca.

---

The Journey Starts Now: Making Evidence Matter for Long-Term Outcomes in IBD

Bruce E. Sands, MD, MS, FACG, Jessica R. Allegretti, MD, MPH, FACG
Omni Nashville Hotel – Legends Ballroom D

Join Dr. Bruce Sands and Dr. Jessica Allegretti as they explore the long-term, comprehensive management of IBD. Through interactive UC and CD patient case discussions, the session will examine long-term efficacy and safety data for IL-23p19 inhibitors and consider how these data may inform treatment decisions.

This program is sponsored by Eli Lilly and Company.

---

The Gastroenterologist’s Guide to Navigating the Complexities of IgG4-Related Disease

Suresh T. Chari, MD, FACG, Yasmin Hernandez-Barco, MD
7:30 pm – 9:30 pm • Omni Nashville Hotel – Broadway Ballroom F

IgG4-related disease (IgG4-RD) mimics malignancies and autoimmune conditions, requiring precise diagnostic criteria to prevent irreversible fibroinflammatory organ damage. This symposium helps HCPs improve diagnostic accuracy and manage high relapse rates by shifting from standard steroids to emerging, targeted therapies for optimized patient outcomes.

This activity is supported by educational funding provided by Amgen.

The New Songs on the Jukebox: TL1A Blockade and Its Emerging Role in IBD

David T. Rubin, MD, MACG (Chair), Jessica R. Allegretti, MD, MPH, FACG, Angelina E. Collins, MSN, ANP-BC, Bruce E. Sands, MD, MS, FACG
7:30 pm - 9:30 pm • Omni Nashville Hotel – Broadway Ballroom G-K

Join leading experts as they explore TL1A as an emerging therapeutic target with the potential to address both intestinal inflammation and fibrosis. Through engaging presentations, discussion, and the interactive Wheel of Knowledge Challenge, explore the scientific rationale for TL1A inhibition, examine the latest clinical data on investigational therapies, and discover how these novel agents may shape the future of IBD management.

This continuing education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

---

The Evolving IBD Landscape: TL1A and Immuno-Fibrosis

Marla C. Dubinsky, MD, Remo Panaccione, MD, FRCPC, Jordan E. Axelrad, MD, MPH, FACG
7:30 pm – 9:00 pm • Omni Nashville Hotel – Broadway Ballroom E

Join leading experts to discuss IBD through the lens of immunofibrosis, with a focus on the interplay of inflammation and fibrosis, the TL1A pathway, and emerging clinical data.

This non-CME symposium is sponsored by Merck.

Finding Your Rhythm – Optimizing IL-23 Inhibitor Use in IBD

Corey A. Siegel, MD, MS (Chair), Adam S. Cheifetz, MD, FACG, Marita Kametas, DNP, MPH, MSN, APN, FNP-BC, COCN, Millie D. Long, MD, MPH, FACG
7:00 pm - 9:00 pm • Omni Nashville Hotel – Broadway Ballroom G-K

Leading experts will review current evidence related to IL-23 inhibition in IBD, how emerging IL-23–targeted therapies may influence individualized treatment decisions, and discuss integrating shared decision-making and interprofessional coordination into IBD management. During the IBD Situation Room, analyze real-world patient scenarios and debate practical management decisions in a fast-paced, interactive learning environment.

This continuing education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Johnson & Johnson.

---

Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes

Edward L. Barnes, MD, MPH, FACG (Moderator), Andres J. Yarur, MD, FACG, Angelina Collins, MSN, ANP-BC
7:00 pm - 9:00 pm • Omni Nashville Hotel – Legends Ballroom E-G

This fast-paced and highly interactive live CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AIbased insights. Learners will see how the immunometabolic impact of visceral and mesenteric adiposity on disease activity, treatment response, and surgical risk translates into practice, what doesn't translate, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply validated adiposity assessment methods, confidently integrate GLP-1 RAs into individualized treatment planning, and deliver patient-centered IBD care.

This continuing education activity is provided by CME Outfitters.

This activity is supported by an educational grant from Lilly.